argenx reports USD 1.7 billion sales growth while argenx stock costs EUR 782.60

Published on 10/27/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Product sales rose 54.00 percent year over year in the third quarter. argenx stock has a December 2026 milestone and USD 3.7 billion in liquidity.

argenx expands its growth pipeline

argenx reported USD 1.7 billion in third-quarter 2026 product net sales, up 54.00 percent year over year.
The company expects Phase 3 empasiprubart data in December 2026 and plans further VYVGART label expansions.
argenx stock was trading at EUR 782.60 at Lang & Schwarz on October 27, 2026 at 4:06 p.m. CEST.

Argenx, NL0010832176, Illustration mit AI erstellt.

argenx stock costs EUR 782.60 at Lang & Schwarz on October 27, 2026, while the company reported USD 1.7 billion in third-quarter product net sales. The result points to a broader growth story built around VYVGART and a growing immunology pipeline, according to argenx on October 22, 2026.

VYVGART remains the earnings engine

VYVGART product net sales increased 54.00 percent from USD 1.1 billion in the third quarter of 2025 to USD 1.7 billion in the third quarter of 2026. The company also reported USD 1.8 billion in total operating income for the quarter, compared with USD 1.2 billion a year earlier.

Profit for the period reached USD 506 million in the third quarter of 2026, up from USD 344 million in the third quarter of 2025. Basic earnings per share rose to USD 8.07 from USD 5.61, while selling, general and administrative expenses included approximately USD 150 million in acquisition-related costs tied to Forte Biosciences.

Pipeline milestones add a second growth pillar

argenx said Phase 3 empasiprubart results in multifocal motor neuropathy are expected in December 2026. The company is also advancing FB102 into Phase 3 development for celiac disease and said a supplemental application for VYVGART Hytrulo in immune-mediated necrotizing myopathy remains on track for submission by year-end 2026.

The balance sheet provides room for that expansion. Cash, cash equivalents and current financial assets totaled USD 3.7 billion as of September 30, 2026, after argenx paid approximately USD 2.1 billion for the Forte acquisition. Combined research and development plus selling and general administrative expenses are expected to reach approximately USD 4 billion for fiscal year 2026.

Stock price and investor perspective

The share price places the market emphasis on whether VYVGART growth can be matched by successful pipeline execution. argenx stock was trading at EUR 782.60 at Lang & Schwarz on October 27, 2026 at 4:06 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.